Win Advisors Inc. Makes New Investment in Thermo Fisher Scientific Inc. $TMO

Win Advisors Inc. acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 944 shares of the medical research company’s stock, valued at approximately $458,000.

Several other institutional investors also recently bought and sold shares of TMO. Atlantic Union Bankshares Corp increased its holdings in shares of Thermo Fisher Scientific by 5.5% during the 3rd quarter. Atlantic Union Bankshares Corp now owns 42,679 shares of the medical research company’s stock valued at $20,700,000 after purchasing an additional 2,240 shares in the last quarter. Convergence Investment Partners LLC purchased a new stake in Thermo Fisher Scientific during the 3rd quarter worth approximately $228,000. Jones Financial Companies Lllp lifted its holdings in Thermo Fisher Scientific by 18.3% in the 3rd quarter. Jones Financial Companies Lllp now owns 152,635 shares of the medical research company’s stock valued at $71,578,000 after purchasing an additional 23,609 shares in the last quarter. Essex Bank grew its stake in Thermo Fisher Scientific by 3.3% during the 3rd quarter. Essex Bank now owns 1,733 shares of the medical research company’s stock valued at $841,000 after acquiring an additional 56 shares in the last quarter. Finally, Oak Harbor Wealth Partners LLC acquired a new stake in shares of Thermo Fisher Scientific in the third quarter valued at approximately $218,000. 89.23% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Thermo Fisher Scientific

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q4 results beat expectations — Adjusted EPS $6.57 and revenue $12.21B (?+7% YoY), driven by life-sciences tools and pharma demand; the print supports near-term organic growth narrative. Read More.
• Positive Sentiment: Analyst support remains — several firms reiterated buys/positive views and one bullish write-up called the pullback a buying opportunity, highlighting resilient margins and competitive positioning. Read More.
• Neutral Sentiment: 2026 guidance set in a narrow band — FY26 revenue guide $46.3B–$47.2B and EPS $24.22–$24.80, roughly around consensus but slightly below EPS midpoint; guidance implies modest 3%–4% organic growth and stabilizing demand. Read More.
• Negative Sentiment: Market reaction focused on cautious profit outlook and margin pressure — despite the beat, investors sold into the print due to conservative margin commentary and a guidance range that doesn’t accelerate growth significantly. Read More.
• Negative Sentiment: Analyst price-target trim — TD Cowen lowered its PT from $696 to $683 while keeping a Buy rating, signaling slightly reduced upside expectations even as coverage stays positive. Read More.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $578.20 on Monday. The stock has a market capitalization of $217.24 billion, a PE ratio of 32.59, a price-to-earnings-growth ratio of 3.82 and a beta of 0.93. The business has a 50 day simple moving average of $593.96 and a 200-day simple moving average of $538.75. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.89 and a quick ratio of 1.53. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, January 29th. The medical research company reported $6.57 earnings per share for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a return on equity of 16.92% and a net margin of 15.05%.The company had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.95 billion. During the same quarter in the previous year, the company earned $6.10 EPS. The firm’s revenue for the quarter was up 7.2% compared to the same quarter last year. Equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific declared that its Board of Directors has approved a share buyback plan on Thursday, November 6th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Thursday, January 15th. Stockholders of record on Monday, December 15th were given a $0.43 dividend. The ex-dividend date was Monday, December 15th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.70%.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, EVP Michael D. Shafer sold 10,725 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $600.00, for a total value of $6,435,000.00. Following the sale, the executive vice president directly owned 18,731 shares in the company, valued at $11,238,600. This represents a 36.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Frederick M. Lowery sold 6,913 shares of the stock in a transaction on Monday, December 1st. The shares were sold at an average price of $597.68, for a total value of $4,131,761.84. Following the sale, the executive vice president directly owned 14,367 shares in the company, valued at approximately $8,586,868.56. The trade was a 32.49% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 124,517 shares of company stock worth $72,363,568. 0.33% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts have commented on the stock. Citigroup lifted their target price on shares of Thermo Fisher Scientific from $660.00 to $685.00 and gave the stock a “buy” rating in a research note on Friday. Redburn Partners set a $580.00 target price on Thermo Fisher Scientific in a research note on Wednesday, October 8th. TD Cowen dropped their price target on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a “buy” rating for the company in a research note on Friday. Morgan Stanley upped their target price on shares of Thermo Fisher Scientific from $656.00 to $670.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 2nd. Finally, UBS Group restated a “neutral” rating and issued a $615.00 price target on shares of Thermo Fisher Scientific in a research note on Friday. One investment analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $633.68.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.